strategic us of Good I'm update performance the afternoon operating to first today. quarter of details over review And to the going results. Tom call QX to our for for thank an our you an overview then, I'll for objectives the and and turn our the year. joining provide on
with commercial Our strategic made solid track to our as goals the year objectives. financial a for we establish off against execution year. both I'm puts is start progress as commercial us on to good our pleased we that recent and momentum meet our
distributor business, goal the during is particularly our million. laboratories priority by product accelerating across was $XX of multiple achieved increased growth quarter in the service clinical customers, first segments Growth our business. as this to top and XX% Our revenue nCounter biopharmaceutical territories. and core We of strong our
quarter. base, XXXX, grew which a as dedicated over months and - reps with To the base of channel. for during sales the In taken by consumable based our at our increasing by XX%, with install reps, strong tangible are to the We XX% consumable added our growth territories life we reps Prosigna, consumable natural the generating we sciences believe are expanded These that first last is consumable stronger both team actions strengthen result a our are of this commercial the this We of pleased productivity inclusive growth installed generated growth than growth particularly having about consumable on revenue. business, impact specialized XX%. sales without commercial creating field tailwind about these help territories leverage our reps. XX
new placements better by win run We to instrument utility to of guidance represented have Our quarter. sales QX increases QX, as research tenders by high for of increasing a offer predictability start to premium leadership the the throughout throughput Europe that under many great the XX% and dual infrastructure the durable are flex dedicated commercial and platforms my use to unit the where more likely just systems team in systems. are had sales Overall, in X% business. visibility commercial of strong our than in the our performance Spread to over was This option implied particularly that paid true nice the our linearity diagnostic grew with products. a customers diagnostic systems the that our Congratulations enhancements year. improvements created conviction quarter. on
me objectives. let strategic Now, to shift our
report in this Our research objective. I'm that on extending making oncology, and leadership our first progress diagnostics. objective to substantial strategic we're is pleased
immune-oncology. primarily placements about markets. accounted first for During XX% year-on-year, quarter, panel instrument driven our XX% by Oncology the revenue direct grew new oncology of within
latest our continue series of last addition our which panel incorporate cancer the top immune of on panels. expanding menu offering research As panel, oncology strategy panels leadership XXX our research The PanCancer remains to for our selling to our profiling maintaining is our development. is fastest elucidate a year drug in and to microenvironment use for growing interactions launch designed is immune immunovation. designed tumor's launched panel are of tumor characterize late and remains and to IO our the panel mechanism content diagnostic The ever XXX
Paris month, world lung example, the PDX with using non-small presented in line research to For from and a inflammation the real XXX conference in panel tumor in research which solid is study the treatment the clinical the signature, [indiscernible] value at IO XXX AACR OPDIVO blockade last demonstrated cancer tumors. IO researchers Their of included second setting. of predictive for cell
the XXX of now the cancer signature Prosigna. for span is the addition, In of that a have launched PAMXX provide the combines we of the power We animal mouse introduced the recently so from a models tools signature, panel, we suite IO clinical which inflammation panel, and basis trials. breast version XXX to tumor that
year, And so This to a drug translational This heterogeneity XXX conference our company a year, later was leading panel to offerings panels management. the customer lymphoma for understand and success quest strength researchers impacts support the We and was their positive indicator in in of far, is cancer high. development this tremendous additional continued patient plan interest to lung and oncology. how created AACR and introduce cancer. in breast with
record were abstracts commercial and technologies presence a number Our our customer XXX generated of in leads. about showcased
about our theater Our of platform. profiling and spatial series who our more spotlight to than grew XXX XXX presentation digital came attendees panels learn
cancer Biopharma. leader about opinion by for addition, attended the and digital from that customers profiling breast XX In were panel Academia hosted XXX dinners we spatial key and
had our commercial achieved We $X milestone for through side of the a breaking first on business. in a quarterly diagnostic also the million major sales time. quarter We Prosigna, for great
to Network tenders. decisions reimbursement accounts In France, following several positive provinces. several win We has for include the into wins coverage to expected begin profiling September, testing If unit the UK, for commonly as of sales, National seeing successful to driving Prosigna Prosigna. geographies, a we our the recently new UK XXXX. recommendation Canada, and as tender success opportunity recommendation in Health catalyzed are hubs Cancer access as Excellence, expect test in more comes ongoing NICE growth across establish in to by known continues In well Institute to gain its adoption in Care in provided all accounts. existing the and as Prosigna this updated gene beginning and effect
continuing Finally, diagnostic menu. we are expand efforts our our to
We robust from companies, preparing approximately ongoing a submit our to In end the the DLBCL number of parallel, we've results pilot QX. increasing study. studies biopharma by X PMA last Phase for our the with the pending LymphMark at to studies over assay, are XX expanded quarter of about XX% engagement
objective Our XXXX nCounter is into drive and therapeutic areas to second new applications. strategic for
matched targeting platform. nCounter the our where of As outside well-funded markets we experimental this described year, oncology research we're are earlier well questions to
neuroscience neuroscience used new immunology cells types profiling and designed prioritized immunology, Within immunology relevant mix oncology We accounting These XX% and panels panels, instrument important driving an that elucidate easy to with and areas instrument about placements NanoString. use market where and already research from quantitative biological us in being developing of gene today: already are well activation those QX. fields. can a during expression playbook borrowing customers made and PCR. immune we to of neuroscience, the by to and for in sale states three for various has the asked is be is successful field are have the questions Immunology of
enabled about XX% customers. accounted During our XXXX, from nCounter of papers the immunology for publications
as clinical along investigating of broad for offered For a a Association Myeloid that developed in panel to and customer panel with panels XXXX, Last Austin, disease. auto coverage auto of immune in benefit we specifically growing Texas, with Immunologists offerings initial inflammation, week, of biomarkers launched such positive. rapidly panel. at of curated targeted therapeutic content the immunology feedback immune identify elucidates are was we this menu for and new past the Conference more profiling, which American our area help several years, of we've a introduced In mechanisms
in The second we've immunology, cell that funding two $XX panels, interest processes, new characterized year, annually. adoption in on panels, neuroscience states and we disease different more of by Much focused entered the dependent last is activation and neuroscience high. other launched still the on early which abundance is on these in billion NIH market the receives of neuropathology of Though than the is one of level neuroinflammation. are types. phases Late neuroscience we like
potential recent grant submitted program. applications Europe neurology our XXX neuroscience approximately example, recent and XX roadshow to through researchers For touched over a couplers
PlexSet, a vastly offering helping Another nCounter our enables is wider QPCR, market. simpler high expression, application new is entry traditionally adoption which workflow which service into drive gene than low throughput plex a
motivate PlexSet During instrument helped several QX, new placements.
interest The selected of the a half region. sequencer. the biopsy of the end. we technology on be designed Our of digital precise the first processing the to to platform novel DSP enable to samples a gene third access And launch protein the of access the in of slides, either under is can next or DSP spatial profiling across objective within spatially and launch of under and these our XXXX, year to now Digital within is late by specific tissue performed or profiling for gene instrument expression full followed of by track regions selection in launch also is generation platform early a the proprietary samples a see nCounter strategic on and commercial designed protein our automate landscape sample. preparation capturing RDSP instrument XXXX. quantification short expression early spatial or is
for with we samples TAP, months, run instruments. customers, level potential the their engagement fee the technology laying avenue or have engagement launch. program, researchers service prototype work several which a our allowing successful a for XXXX past is our is Over increased program access substantially our on for One ground to DSP of
first week, to DSP nine that access the customers. we leading total immune-oncology services, expand models first expanded XX. our TAP orientation. of announced projects spatial a DSP organizations particularly Last new and have also among initiated using with quarter, panel the contract field to with of the mouse partnered projects, biopharma neuroscience, to cover panels We've such a we During DSP research menu for introduced to we bringing strong number
will We services groups Genetics, biopharma they customers. have which now already be offer FISH and signed will laboratories agreement CROs, IHC to select their become analysis with These Diagnostics with Covance, UK. services these including available. Solutions, when NanoString performed Cancer conventional technologies and QX instruments TAP Propath labs using market our Initially, able will under existing spatial DSP acquire Core five the but DSP expect to program, that we be
increased during conference. its In presented prospective researchers buzz our abstracts, major genome meeting. DSP. commercial of addition, and to during at generated and four featured DSP last when highlighting applications interest strongly presence customers. NanoString momentum scientific to introduce DSP AGBT the year, conferences Earlier and At Customer annual the capabilities we're this using among substantial AACR, DSP collaborators was month the AACR
to non-spatial observed that therapy anti-PDX biomarker and from an Rimm characterize receiving particular to biomarkers XX-plex University Each by used clinical and type, David pretreatment five DSP which a and is novel Professor using identified melanoma response. predicted on First, a spatial Yale have grind tied from bind samples that panel protein would assays. traditional cell profiling insight been was not enabled patients
RNA DSP reproducible researchers cancer cell Second, flow Genentech program access with from profiling and technology strong highly ran from through concordance both non-small who cytometry immunohistochemistry. demonstrated our and lung
in study DSP concept of Third, XXXX significant the spatial advances using with proof simultaneously capability NanoString RNA the networks entire resolution. team profiling them signaling read to RNAs to out, demonstrated reconstruct allowing characterize NGF with a
we qualified for cost. version leads, the use highly was the into the of $XXX,XXX price demonstrated and meetings the we program. Customer samples, of which that and provided customer DSP simplicity have quoting AACR, XX utility back built team of panel workflow. really or for demonstrated software DSP DSP XXX pre-clinical and the were to TAP under AACR NanoString first been and in demonstrated our research. analyze a Finally, feedback from for at their push interest generated submission suite with DSP platform instrument projects reality our booth about explore no alpha a DSP on list through DSP a extending grant fantastic DSP unveiled private instrument, the virtual data customer used the In experience our the mouse at of our of an on study
that are We DSP confident will an be than and more ever growth catalyst. platform XXXX now important
commercial Our the for launch a toward fourth year Hyb our strategic to in is advance & XXXX. objective Seq platform
opportunities February. We're to development and that our came continue AGBT projects, demonstration of several Hyb on platform. make steady including collaborations for discussing Hyb Seq progress Seq We & new in the the conference out customer & currently of
and been In addition, the reimbursement turnaround Hyb fronts. efforts simultaneous important compelling and we've suggest have expanded the DNA on regulatory our developments and market Seq. of results and sequencing XX-hour time & RNA there research both features that Meanwhile, are for
First, framework validation assays, based design, NGS development recently NGS-based the finalized US Food and for Drug a guidance of tests. diagnostic and Administration on establishing companion
cancer. a updating determination you and developments on Services Seq. the these in term in progress Centers long panels to & Seq for campaign Hyb make diagnostic future on for more sequencing Hyb national issued opportunity Medicare based on Second, positive on commercial Medicaid the quarters. I continued forward our & Together, advanced the program for coverage look us
the first our for financial guidance the over call review and our results Now, I'll turn provide Tom to for quarter QX. to
